Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicentre Study To Assess Changes In Bone Mineral Density Of The Switch From Tenofovir To Abacavir In HIV-1-Infected Subjects With Loss Of Bone Mineral Density

Next Previous
Trial Profile

Multicentre Study To Assess Changes In Bone Mineral Density Of The Switch From Tenofovir To Abacavir In HIV-1-Infected Subjects With Loss Of Bone Mineral Density

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 25 Dec 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abacavir (Primary) ; Antiretrovirals; Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate; Emtricitabine; Emtricitabine/tenofovir disoproxil fumarate; HIV protease inhibitors; Lamivudine; Non-nucleoside reverse transcriptase inhibitors; Raltegravir; Tenofovir disoproxil fumarate
  • Indications HIV-1 infections
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms OsteoTDF; OSTEOTENOFOVIR

Most Recent Events

  • 06 Mar 2013 Interim results (n=48) presented at the 20th Conference on Retroviruses and Opportunistic Infections.
  • 03 Oct 2011 Planned End Date changed from 1 Dec 2011 to 1 Jun 2012 as reported by ClinicalTrials.gov
  • 03 Oct 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top